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ABSTRACT
Objectives: To derive robust estimates for the cost of mul-
tiple sclerosis (MS) based on a variety of cost factors across a
number of different cost perspectives. This is essential to
perform credible pharmacoeconomic evaluations of alterna-
tive MS therapies.
Methods: Here we present a detailed analysis of previously
published MS cost data for the UK to which we ﬁt a seem-
ingly unrelated regression. This allows us to assess the size
and signiﬁcance of different cost factors, and account for the
covariance between cost perspectives.
Results: We show that disability severity, disease type,
relapse status, treatment type and time of treatment, sex, age,
educational status, and time since diagnosis, are signiﬁcant
cost factors, with the signiﬁcance of each dependent on the
cost perspective chosen.
Conclusions: This analysis provides a statistical model that
may be used to better estimate individual patient costs across
a range of demographic and cost perspectives, for use by
health planners and in pharmacoeconomic evaluations.
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Introduction
Multiple sclerosis (MS) is a neurological disease char-
acterized by areas of demyelination (lesions) within the
central nervous system. These lesions affect the normal
functioning of the nerves involved, and an accumula-
tion of MS lesions over time results in irreversible
physical and neurological impairment [1]. People with
MS can experience acute exacerbations of symptoms
between periods of stable disease (relapsing-remitting
MS or RRMS), or a gradual increase in disability over
time with or without acute relapses (primary progres-
sive MS or PPMS). People with the remitting forms of
MS can subsequently experience progressive disease
(secondary progressive MS or SPMS). Disability sever-
ity for each form is generally measured using the
Extended Disability Severity Scale (EDSS), which
ranges from EDSS 0 (normal neurologic examination)
to EDSS 10 (death because of MS) in half-point
increments from EDSS 1.
Here we present the results of a detailed cost analy-
sis of MS in the UK that are derived from a large UK
study. The UK study was part of a European study [2].
In assessing the cost of MS it was considered necessary
to distinguish between the three forms of MS as well as
disability severity and relapse, and it is these that form
the basis of the cost estimates. Because the cost per-
spectives will vary between health planners, it was also
considered necessary to separate costs into categories
according to who pays. A number of additional cova-
riates thought to affect cost were also included in
analysis. The cost model would therefore be structured
to enable estimates of cost to be made for a variety of
patients from a number of different cost perspectives.
Methods
Study methods, baseline characteristics and utility
coefﬁcients from the UK study have been previously
reported by Orme et al. [3]. Here we report costs by
EDSS state after controlling for other factors that
may inﬂuence costs. The outcomes assessed are the
amounts paid during a one-year period for ﬁve cost
categories. The survey collected a number of factors
and variables for patients, which can be used as pre-
dictive variables. These were age, sex, marital status,
education, disease (RRMS, PPMS, or SPMS), recent
relapse status within three months before the survey,
number of years since diagnosis, disability (EDSS 0 to
EDSS 9), and disease-modifying drug (DMD). The
societal cost perspective for the UK is considered here,
and is broken down into ﬁve cost categories. These are
direct medical costs funded by government (DMG),
direct-medical costs funded out-of-pocket (DMOP),
direct nonmedical costs funded by government
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(DNMG), direct nonmedical costs funded out-of-
pocket (DNMOP), and indirect costs (IND).
The time periods over which different resources
were measured were taken from Henriksson et al. [4],
then standardized to one year. Data for 115 different
resources were available from the questionnaire, which
gave the quantity of each resource used per person.
These were multiplied by the cost of each unit to ﬁnd
the cost per person per year. Unit costs older than
12 months were inﬂated to May 2005 costs using a
3.5% discount rate. The unit costs were sourced from
appropriate UK-published sources.
For each of the cost categories, independent multi-
variate linear regression was undertaken including all
possible covariables. A step down procedure was used
to drop the least signiﬁcant term from the model, until
only signiﬁcant (P < 0.05) covariables remained. The
signiﬁcance of the set of coefﬁcientsmaking up categori-
cal covariables with more than two levels was assessed
by ANOVA. The interaction of DMD with EDSS was
assessed for the direct medical costs by dividing EDSS
into three states (0–2, 3–6.5, and 7–9). This analysis
produced ﬁve regression equations, each with a set of
covariables used to explain the total cost in each cat-
egory. The cost per category for a given person is not
independent (e.g., a personwith highDMGcosts would
also be expected to have high DNMG costs). This
correlation between costs is modeled using seemingly
unrelated regression (SUR) [5]. In this model, instead of
the error terms in the ﬁve regression equations being
independent of each other, both within and between
people, the error term for each person is sampled from
a multivariate normal distribution. In this way there is
now dependence on costs within a person, but still
independence between people. The model ﬁtting is
achieved using the system ﬁt package in R [6]. The SUR
estimates covariate parameters, and from these the
mean cost for a patient with any given set of character-
istics can be estimated. The reference case is a married
woman aged 30 years, with RRMS, diagnosed ﬁve
years ago, EDSS 0, educated to secondary school level,
with no recent relapse, and not receiving a DMD. Any
alteration in one or more of the patient characteristics
from the reference case alters the value of one or more
of the cost categories.
Results
A total of 12,698 surveys were mailed and 2,508
responders returned signed surveys before the deadline
Table 1 Direct government-funded costs
Coefﬁcient Estimate (£) SE (£) 95% CI (£) P-value
a. Direct annual medical cost coefﬁcients funded by UK government (DMG)
EDSS 0† 250 1,975 (-3,623, 4,123) 0.90
EDSS 1 85 899 (-1,678, 1,849) 0.92
EDSS 2 213 868 (-1,489, 1,915) 0.81
EDSS 3 850 1,237 (-1,575, 3,275) 0.49
EDSS 4 806 884 (-927, 2,539) 0.36
EDSS 5 1,419 823 (-195, 3,032) 0.09
EDSS 6 2,162 851 (492, 3,832) 0.01
EDSS 6.5 3,429 909 (1,645, 5,212) *
EDSS 7 6,583 995 (4,632, 8,534) *
EDSS 8 10,761 1,069 (8,665, 12,857) *
EDSS 9 15,121 2,656 (9,912, 20,330) *
RRMS†
SPMS 280 705 (-1,103, 1,663) 0.69
PPMS -1,517 815 (-3,114, 81) 0.06
Relapse 1,623 545 (554, 2,692) *
DMD + EDSS 0–2 9,174 1,161 (6,896, 11,452) *
DMD + EDSS 3–6.5 467 1,349 (-2,179, 3,113) 0.73
DMD + EDSS 7–9 -689 3,735 (-8,015, 6,636) 0.85
b. Direct annual nonmedical cost coefﬁcients funded by UK government (DNMG)
EDSS 0† 2,536 2,183 (-1,745, 6,817) 0.25
EDSS 1 3,462 1,314 (886, 6,039) 0.01
EDSS 2 4,414 1,314 (1,836, 6,991) *
EDSS 3 6,212 1,585 (3,103, 9,321) *
EDSS 4 4,028 1,320 (1,439, 6,617) *
EDSS 5 6,333 1,338 (3,709, 8,958) *
EDSS 6 6,580 1,338 (3,956, 9,204) *
EDSS 6.5 8,212 1,398 (5,471, 10,953) *
EDSS 7 10,808 1,485 (7,895, 13,721) *
EDSS 8 15,339 1,514 (12,369, 18,309) *
EDSS 9 10,161 2,837 (4,598, 15,725) *
Age -66 25 (-116, -16) 0.01
Years since diagnosis 54 29 (-2, 110) 0.06
*P < 0.01. †Reference case.
CI, conﬁdence interval.
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(19.3%); 2,048 people are included in the analysis
(15.8%). The demographic, disease status, dropouts
and breakdown of people at each EDSS state is
reported elsewhere [3]. The cost for the reference case
is £6,947, but the annual cost of MS exceeds £40,000
per patient per year in the latter stages of disease.
Table 1 presents the coefﬁcients for estimating direct
government-funded costs by category, for certain
patient characteristics. Table 2 provides these coefﬁ-
cients for direct out-of-pocket costs and IND. The
P-values in these tables correspond to a two-tailed test
of the null hypothesis that an EDSS state coefﬁcient is
different from zero, a categorical coefﬁcient (disease
type or education) is different from the reference cat-
egory, or a continuous coefﬁcient is different from
zero.
A large amount of variation in cost occurs across
both cost categories and EDSS score, with the most
severe states of disability incurring the greatest costs.
IND is the greatest cost category.
Direct medical costs (DMG, Table 1a) up to EDSS 4
are not signiﬁcantly different from zero, reﬂecting large
variation and relatively low values. DMG costs
increase with corresponding EDSS increase between
Table 2 Direct out-of-pocket and indirect cost
Coefﬁcient Estimate (£) SE (£) 95% CI (£) P-value
a. Direct annual medical cost coefﬁcients funded out-of-pocket (DMOP)
EDSS 0† 22 135 (-242, 286) 0.87
EDSS 1 77 63 (-46, 200) 0.22
EDSS 2 110 56 (0, 220) 0.05
EDSS 3 214 82 (53, 374) 0.01
EDSS 4 241 56 (132, 351) *
EDSS 5 245 44 (159, 332) *
EDSS 6 286 41 (206, 366) *
EDSS 6.5 321 45 (233, 409) *
EDSS 7 371 53 (268, 474) *
EDSS 8 409 57 (296, 521) *
EDSS 9 821 175 (477, 1,165) *
Edu. Secondary School†
Edu. College 112 40 (33, 191) 0.01
Edu. University 87 39 (11, 163) 0.03
Edu. Postgraduate 267 55 (158, 375) *
b. Direct annual nonmedical cost coefﬁcients funded out-of-pocket (DNMOP)
EDSS 0† 1,780 1,223 (-619, 4,178) 0.15
EDSS 1 1,214 518 (198, 2,230) 0.02
EDSS 2 1,035 470 (113, 1,957) 0.03
EDSS 3 1,527 730 (95, 2,958) 0.04
EDSS 4 1,200 462 (293, 2,107) 0.01
EDSS 5 1,344 357 (645, 2,044) *
EDSS 6 1,358 323 (725, 1,990) *
EDSS 6.5 2,312 365 (1,596, 3,028) *
EDSS 7 1,944 439 (1,084, 2,805) *
EDSS 8 1,498 498 (521, 2,474) *
EDSS 9 288 1,610 (-2,870, 3,447) 0.86
c. Indirect annual cost coefﬁcients (IND)
EDSS 0† 11,509 1,633 (8,306, 14,711) *
EDSS 1 12,857 1,034 (10,829, 14,886) *
EDSS 2 17,068 1,010 (15,087, 19,049) *
EDSS 3 19,450 1,191 (17,114, 21,786) *
EDSS 4 16,049 1,013 (14,062, 18,037) *
EDSS 5 21,116 1,029 (19,099, 23,133) *
EDSS 6 21,338 1,042 (19,294, 23,381) *
EDSS 6.5 21,937 1,094 (19,791, 24,083) *
EDSS 7 22,736 1,161 (20,459, 25,013) *
EDSS 8 23,088 1,169 (20,796, 25,380) *
EDSS 9 23,583 2,107 (19,451, 27,715) *
RRMS†
SPMS 1,166 496 (193, 2,140) 0.02
PPMS -484 549 (-1,560, 592) 0.38
Female†
Male 1,948 378 (1,207, 2,689) *
Age -248 18 (-283, -213) *
Edu. Secondary School†
Edu. College -392 422 (-1,220, 436) 0.35
Edu. University -478 407 (-1,277, 320) 0.24
Edu. Postgraduate -1,657 581 (-2,797, -516) *
*P < 0.01.
†Reference case.
CI, conﬁdence interval.
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EDSS 5 and EDSS 9. Also SPMS is not signiﬁcantly
different from the reference case, indicating that the
direct medical costs for RRMS and SPMS are similar.
DMD is a very large factor with respect to DMG costs.
For the direct nonmedical costs (DNMG Table 1b),
the difference in EDSS state from zero is signiﬁcant
across all EDSS states except EDSS 0. Here increasing
age results in a reduction in costs.
Out-of-pocket costs (direct medical and direct non-
medical) are relatively small compared with the other
cost categories (DMOP and DNMOP in Table 2a and
Table 2b, respectively). Nevertheless, although DMOP
does increase with EDSS state, there is little variation
across EDSS states for DNMOP. DMOP cost also
increases with education above secondary school level.
The greatest individual cost category is IND
(Table 2c). Here the increase in cost with increasing
EDSS states is substantial and plateaus after EDSS 5.
Also the IND due to SPMS is higher, the cost for males
is higher, and cost decreases with age. The IND for
those with postgraduate education is lower.
Discussion
The cost of MS typically follows a U-shaped distribu-
tion, being greater during lower EDSS states because of
the use of DMD drugs, and greater at high EDSS states
because of the high cost of care and IND. The Asso-
ciation of British Neurologists recommends stopping
DMD treatment once the person has lost the ability to
walk, equivalent to an EDSS score of 6.5 [7]. We see
IND rise dramatically around this stage representing
an increase in unemployment, which rises from 5% at
EDSS 1 to 52% at EDSS 5, and then more slowly to
79% at EDSS 9 (the mean unemployment rate for the
study population is 46%). Direct out-of-pocket expen-
diture (DMOP plus DNMOP) is consistently between
£1,100 and £2,600 for all EDSS states, representing
an increasing burden on patients as earning power
diminishes.
Our analysis has been reported to update and reﬁne
the understanding of direct and IND of MS in the UK.
The coefﬁcients we report can be used to assist service
and commissioning managers plan future services for
MS, and as a basis for cost-effectiveness analyses of
new interventions. Comparing these results to similar
studies it can be seen that the cost of MS is large and
increases with disability severity. The humanistic ratio-
nale for intervening to delay the progression of MS is
well recognized. This study provides a ﬁnancial ratio-
nale to support interventions that delay progression.
The questionnaire for the study was based on a questionnaire
devised and reﬁned by Dr Gisela Kobelt. The UK MS Trust
and UK MS Society advised on the wording of the question-
naire and resources most commonly used in the UK by people
with MS. Three health-care professionals provided the list of
drugs used by people with MS in the UK.
Source of ﬁnancial support: Biogen Idec UK provided funding
for this study.
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